A General Immune Boost Instead of a Specific Target

Most cancer immunotherapies rely on identifying and attacking neoepitopes—proteins that arise from mutations specific to a patient’s tumor. This approach works best in cancers with high mutation loads, such as melanoma, but has limited success in tumors with low mutational burden. A study published in Nature Biomedical Engineering and conducted by scientists at the University of Florida challenges that model.

In their experiments, researchers used an experimental mRNA vaccine delivered via lipid nanoparticles, similar to the technology used in COVID-19 vaccines. But instead of encoding a viral protein, this vaccine instructs the immune system to produce proteins that activate an immune response.

One of these proteins, PD-L1, is commonly found on cancer cells and helps them evade immune detection. By artificially inducing PD-L1 expression in tumors, the vaccine made the cancer cells more visible to the immune system, improving the effects of immune checkpoint inhibitors.

Making Resistant Tumors Respond to Treatment

In mouse models of melanoma, the mRNA vaccine cleared drug-resistant tumors and triggered “antigenic spreading”—a process where the immune system begins to recognize and attack multiple tumor-related antigens. In some cases, the vaccine worked even without additional treatments. It was also tested in models of brain, skin, and bone cancers with similarly promising results.

Researchers demonstrated that tumors resistant to checkpoint inhibitors lacked these early immune signals, but became sensitive when treated with RNA-loaded lipid particles that boosted interferon activity. This led to a broader immune reaction, enabling previously unresponsive tumors to respond to immunotherapy.

Together, these results highlight a new paradigm in cancer treatment: instead of customizing a vaccine to match each patient’s unique tumor profile, it may be possible to create a general-purpose vaccine that teaches the immune system to react aggressively to cancer, regardless of the tumor’s specifics.

Laying the Groundwork for an Off-the-Shelf Cancer Vaccine

Dr. Elias Sayour, a pediatric oncologist at the University of Florida and lead investigator on the study, described the results as “a proof of concept” that such a vaccine could eventually become an off-the-shelf solution. Co-author Dr. Duane Mitchell added that this approach may pave the way for more accessible and broadly applicable cancer treatments.

While these findings are based on animal studies, they offer a strong foundation for clinical research. If the vaccine proves effective in humans, it could significantly improve cancer immunotherapy, especially for patients with tumors that previously showed little to no response.

The research not only expands the potential use of mRNA technology beyond infectious disease but also underscores the power of immune system priming. As development continues, a universal cancer vaccine may soon become a powerful tool in the fight against one of the world’s most complex diseases.

[Source]

The post Universal Cancer Vaccine Shows Promise in Boosting Immunotherapy Response appeared first on Medical Journal Daily.

The study, published in the British Journal of Sports Medicine, evaluated high-quality meta-analyses of randomized controlled trials. The evidence strongly supports the integration of exercise into cancer treatment protocols, particularly when compared to usual care or no exercise at all.

Exercise Reduces Key Side Effects of Cancer Treatment

The review highlights that exercise helps counteract several serious side effects commonly experienced during cancer treatment. One of the most notable benefits is the reduction in cardiotoxicity—heart damage often caused by chemotherapy—which was significantly less in patients who engaged in physical activity.

Exercise also proved effective in managing chemotherapy-induced peripheral neuropathy (CIPN), a condition that leads to nerve damage and affects balance and coordination. Cognitive impairment, often described as “brain fog,” improved in patients who exercised regularly, with many reporting better mental clarity and reduced fatigue. Additionally, dyspnoea, or shortness of breath, frequently seen in lung and advanced-stage cancers, was also alleviated through consistent physical activity.

Beyond physical health, exercise was found to positively impact several quality-of-life indicators. These included improved sleep quality, reduced stress and anxiety, and enhanced social interaction. This is particularly relevant as many cancer patients struggle with isolation and emotional fatigue during treatment.

Importantly, the review showed moderate- to high-certainty evidence that preoperative exercise reduced post-surgery complications, length of hospital stay, and even mortality.

In addition to subjective outcomes, researchers noted changes in biological markers. Levels of insulin, insulin-like growth factor 1 (IGF-1), and C-reactive protein (CRP)—all key indicators of inflammation and metabolic health—were positively influenced by exercise. Body composition also improved, with patients experiencing healthier muscle-to-fat ratios.

Various Forms of Exercise Prove Effective

The review included a range of physical activities: aerobic training, resistance exercise, high-intensity interval training (HIIT), tai chi, and yoga. All were associated with measurable benefits. This suggests patients can choose the type of exercise that best suits their health status and personal preferences.

Mind-body practices like yoga and tai chi not only improved physical symptoms but also supported emotional and mental health. This flexibility in approach makes it easier for clinicians to recommend activity plans tailored to individual patients.

Given the moderate- to high-certainty of the findings, the study’s authors advocate for exercise to become a standard component of cancer treatment. Currently, many cancer patients receive limited or no guidance on physical activity during their care journey.

Implications for Cancer Care Protocols

While the study underscores the value of exercise, experts also emphasize the need for personalized programs. As Celene Doherty from Cancer Research UK noted, patients should engage in exercise at their own pace and consult with their care teams for appropriate guidance.

This umbrella review provides strong, evidence-based support for including structured exercise in cancer care. From reducing cardiotoxicity and nerve damage to enhancing sleep and emotional well-being, the health benefits are wide-ranging.

The findings encourage oncologists to consider integrating physical activity into standard treatment plans, offering patients not just extended survival but improved day-to-day quality of life.

[Source]

The post Exercise Significantly Reduces Cancer Treatment Side Effects Major Review Finds appeared first on Medical Journal Daily.

Developed by the British biotech firm Xgenera alongside researchers from the University of Southampton, the test examines microRNA—fragments of genetic material linked to cancer activity. These markers are then processed using AI to detect if cancer is present and where in the body it may be.

A Blood Sample Instead of a Biopsy

For many cancers, diagnosis still depends on methods like colonoscopies or biopsies, which can be stressful and time-consuming. This new approach requires just a small vial of blood. Once analyzed, the AI system can flag the presence of cancer cells with a reported accuracy of over 99%.

The test targets a wide range of cancers including bowel, breast, lung, prostate, pancreatic, and others. This broad reach is one of the reasons it’s being considered as a future screening tool.

Who’s Part of the Trial and What They Hope to Prove

Roughly 8,000 people will take part in the NHS trial—some already showing signs of illness, others not. The idea is to measure the test’s performance across a variety of conditions and confirm how it might work if used more broadly in routine care.

To support its development, the UK government has allocated £2.4 million toward the project. Secretary Wes Streeting, who himself has undergone cancer treatment in the past, early and accurate detection is essential if survival rates are to improve. He called this initiative a step toward speeding up diagnosis and easing the burden on NHS services.

Making It Fast, Scalable, and Cost-Effective

One of the biggest challenges in cancer care is catching the disease early without overwhelming health systems. Known as miONCO-Dx, the blood test could provide a practical alternative to conventional cancer detection methods. It only needs 10 to 15 drops of blood and costs far less than current diagnostic tools—estimated between £120 and £300 per test.

Andy Shapanis, who leads Xgenera, says the real goal is to develop something that could work at a national level. “We’re looking at a tool that can operate at scale without sacrificing accuracy,” he explained. In early tests, the technology performed equally well in detecting early- and late-stage cancers.

Building the Foundation for National Cancer Screening

If the full trial goes well, this test might one day be offered as part of standard NHS checkups. That could significantly cut down on diagnostic delays and reduce the need for more invasive investigations.

Bowel cancer, for example, is among the illnesses this test could detect. While it’s the third most common cancer in the UK, it often goes unnoticed until it’s too late. When diagnosed in its early stages, bowel cancer has a survival rate close to 90%. But if it’s detected late, that rate can fall dramatically to around 10%.

Research and further development will continue at the newly renamed BowelBabe Laboratory at the Francis Crick Institute in London. The facility honors the legacy of Dame Deborah James, who died of bowel cancer in 2022 and raised millions for research before her passing.

This project is also part of a wider national plan to modernize cancer care and make the latest detection technologies more accessible to patients across the UK. As Professor Lucy Chappell of the National Institute for Health and Care Research put it, tools like this bring us closer to faster, easier, and more accurate diagnoses—just when patients need it most.

[Source: 1,2]

The post NHS Trials Blood Test to Detect 12 Common Cancers with Over 99% Accuracy appeared first on Medical Journal Daily.

An international review examining global dietary patterns revealed that those consuming a Western diet, characterized by high fat and sugar intake, face an increased risk of colorectal cancer and Inflammatory Bowel Disease (IBD).

Published in the journal Nature Reviews Microbiology, the study analyzed how diet affects the gut microbiome – the community of microorganisms in our intestines – and how changes in its composition influence overall health.

“Our review highlights the profound impact of different diets on the gut microbiome,” stated lead author Prof. Catherine Stanton. “This understanding is crucial for developing dietary recommendations that promote health and prevent disease. It’s fascinating to see how dietary choices can influence the balance of microorganisms in our gut and their metabolic functions.”

The research compared six prevalent diets – Mediterranean, high-fiber, plant-based, high-protein, ketogenic, and Western – to determine their effects on gut bacteria associated with intestinal disorders.

Findings indicate that a Western diet rich in processed foods, red meat, sugary beverages, and high-fat products poses the highest risk. Conversely, a Mediterranean diet high in fruits and vegetables has the lowest risk and helps manage conditions like cardiovascular disease, IBD, and type 2 diabetes.

The study suggests that healthcare professionals could use these insights to develop targeted nutritional therapies to improve public health outcomes.

“This review is a significant milestone in microbiome research,” said Prof. Paul Ross, Director of APC Microbiome Ireland. “It provides a detailed look at how dietary patterns shape the gut microbiome and underscores the potential for diet-based interventions in clinical practice. It provides tangible data on how the microbiome is intrinsically relevant to creating health benefits for society.”

Research shows that while some cancers are declining in older adults, cancer is increasingly being diagnosed in younger individuals, often before the age of 50. A recent study found that early-onset cancer cases “increased substantially” from 2010 to 2019, with breast cancer being the most common and gastrointestinal cancers growing the fastest.

Early-onset cancers, diagnosed in adults aged 18 to 49, tend to be more aggressive and less responsive to treatment.

The American Cancer Society reports that colorectal cancer is the leading cause of cancer deaths in men under 50 and the second leading cause of death in women under 50, following breast cancer. In early 2023, it was reported that 20% of colorectal cancer diagnoses in 2019 were in patients under 55, nearly double the rate in 1995, with advanced disease rates increasing by about 3% annually in people younger than 50.

Researchers find the increase in cases concerning, particularly because individuals in this age group are often too young for recommended routine cancer screenings, leading to delayed diagnoses and more advanced, harder-to-treat cancer.

“There is often a delay between the onset of symptoms and the actual diagnostic procedure to find the cancer,” said Jeremy Kortmansky, a Yale Medicine medical oncologist specializing in gastrointestinal cancers. “Some of that may be driven by patients who think, ‘I’m only 40—it’s probably not cancer, right?’ Other times, a physician may think rectal bleeding in a young patient is just a sign of hemorrhoids, so it’s important to advocate for yourself.”

The reasons behind the vulnerability of younger people to cancer diagnoses remain unclear, though several risk factors have been suggested.

Some research points to the increasing incidence of obesity, changes in environmental exposures like smoke and gasoline, sleep patterns, physical activity, microbiota, and transient exposure to carcinogenic compounds as potential contributors.

According to the American Cancer Society, nearly 1 in 5 cancers is linked to excess body weight, alcohol consumption, unhealthy diet, and physical inactivity.

1. Nature Reviews Microbiology. (2024). Impact of Dietary Patterns on the Gut Microbiome. Nature. doi:10.1038/s41579-024-01068-4.
2. APC Microbiome Ireland. (2024). Western Diets Pose Greater Risk of Cancer and IBD. University College Cork. Retrieved from https://www.ucc.ie/en/apc/news/apc-news/apc-study-finds-western-diets-pose-greater-risk-of-cancer-and-ibd.html
3. Yale Medicine. (2024). Early-Onset Cancer in Younger People on the Rise. Yale Medicine. Retrieved from https://www.yalemedicine.org/news/early-onset-cancer-in-younger-people-on-the-rise
4. JAMA Network. (2024). Incidence of Early-Onset Cancer in Younger Adults. JAMA Network Open. doi:10.1001/jamanetworkopen.2024.8381.

The post Researchers Uncover Diet’s Role in Rising Colon Cancer Rates Among Young Adults appeared first on Medical Journal Daily.

Research Findings

The research, conducted by the University’s Global Academy of Agriculture and Food Systems and the University of North Carolina, Chapel Hill, utilized a simulation tool to assess the health impacts of reducing both processed and unprocessed red meat consumption. Previous studies have shown links between high processed meat intake and chronic diseases, but this study is unique in evaluating multiple health outcomes.

Methodology

Researchers created a microsimulation using data from a Centers for Disease Control and Prevention (CDC) national health survey, representing the US adult population. This simulation estimated the effects of reducing meat consumption on risks of diabetes, cardiovascular disease, colorectal cancer, and overall mortality. The impacts were analyzed across different demographics, including age, sex, household income, and ethnicity.

Significant Health Benefits

A 30% reduction in processed meat consumption could prevent 92,500 cases of cardiovascular disease and 53,300 cases of colorectal cancer over ten years. The benefits were most pronounced among white males and individuals with annual household incomes between $25,000 and $55,000.

The researchers also examined the effects of reducing both processed and unprocessed red meat. A 30% reduction in both led to a substantial decrease in disease cases, including 1,073,400 fewer diabetes cases, 382,400 fewer cardiovascular disease cases, and 84,400 fewer colorectal cancer cases. Reducing only unprocessed red meat intake by 30% could prevent over 732,000 diabetes cases, 291,500 cardiovascular disease cases, and 32,200 colorectal cancer cases.

Remaining Uncertainties

While the study highlights significant health benefits from reducing meat consumption, uncertainties remain, particularly regarding the impact of unprocessed red meat. The average daily intake of unprocessed red meat is higher than processed meat, which may explain the more substantial reduction in disease cases when unprocessed red meat consumption is reduced.

References:

1. Jaacks, L. M., Vandevijvere, S., Pan, A., et al. (2024). Health and environmental impacts of reducing processed meat consumption: A microsimulation study in the United States. The Lancet Planetary Health, Article.
2. University of Edinburgh. (2024). Cutting processed meat intake brings health benefits. News Release.

The post Cutting Processed Meat by 30% Prevents 350,000 Diabetes Cases appeared first on Medical Journal Daily.